Analyzing the Clinical Safety of Sequential Therapy with Azithromycin in the Treatment of Mycoplasma Pneumonia in Children
Objective To investigate the therapeutic effect of sequential therapy with azithromycin in children with mycoplasma pneumonia.Methods A total of ninety children with mycoplasma pneumonia admitted to Wuzhong People's Hospital of Suzhou City from October 2022 to October 2023 were non-randomly selected as the study ob-jects,and were divided into control group(ceftriaxone treatment)and observation group(azithromycin sequential therapy)according to different treatment methods,forty-five cases in each group.The total effective rate,incidence of adverse reactions,humoral immune function indexes and inflammatory factors were compared between the two groups.Results The total effective rate of the observation group was 97.78% (44/45),which was higher than 77.78%(35/45)of the control group,the difference was statistically significant(χ2=8.389,P<0.05).The incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).After treatment,the humoral immune function indexes of the observation group were better than those of the control group,and the differences were statistically significant(all P<0.05).After treatment,the levels of inflammatory factors in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).Conclusion Sequential therapy with azithromycin can improve the cure rate and prognosis in the treatment of pediatric mycoplasma pneumonia.
万方数据
维普
